Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Harrington

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Hemasphere|August 12, 2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsAndrea Duminuco, Joshua Au Yeung, Raj Vaghela, et al.
Leukemia Research Reports|January 2, 2023
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, et al.
Hemasphere|July 8, 2021
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral CenterAlesia Khan, Claire Woodley, Deepti Radia, et al.
Cancer Cell|October 31, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
Cancer Cell|December 15, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
Hemasphere|June 28, 2021
Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021Jamie Saunders, Natalia Curto-Garcia, Priya Sriskandarajah, et al.
Blood Advances|September 9, 2022
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disordersPatrick Harrington, Ashwini Kurshan, Marc Delord, et al.
Haematologica|September 25, 2025
Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinibJasmine Makker, Kyaw Htin Thaw, Amna Sheikh, et al.
Leukemia|May 23, 2021
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsPatrick Harrington, Hugues de Lavallade, Katie J Doores, et al.
British Journal of Haematology|June 4, 2021
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemiaPatrick Harrington, Katie J Doores, Deepti Radia, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Hemasphere|August 12, 2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsAndrea Duminuco, Joshua Au Yeung, Raj Vaghela, et al.
Leukemia Research Reports|January 2, 2023
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, et al.
Hemasphere|July 8, 2021
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral CenterAlesia Khan, Claire Woodley, Deepti Radia, et al.
Cancer Cell|October 31, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
Cancer Cell|December 15, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
Hemasphere|June 28, 2021
Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021Jamie Saunders, Natalia Curto-Garcia, Priya Sriskandarajah, et al.
Blood Advances|September 9, 2022
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disordersPatrick Harrington, Ashwini Kurshan, Marc Delord, et al.
Haematologica|September 25, 2025
Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinibJasmine Makker, Kyaw Htin Thaw, Amna Sheikh, et al.
Leukemia|May 23, 2021
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasmsPatrick Harrington, Hugues de Lavallade, Katie J Doores, et al.
British Journal of Haematology|June 4, 2021
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemiaPatrick Harrington, Katie J Doores, Deepti Radia, et al.
Pageof 5